Corium International, Inc. (CORI) Upgraded to Hold by BidaskClub
BidaskClub upgraded shares of Corium International, Inc. (NASDAQ:CORI) from a sell rating to a hold rating in a research note issued to investors on Friday morning.
Other research analysts also recently issued research reports about the stock. Jefferies Group LLC reiterated a buy rating and set a $8.00 price target on shares of Corium International in a research report on Wednesday, July 19th. Zacks Investment Research downgraded shares of Corium International from a buy rating to a hold rating in a research report on Tuesday, July 11th. ValuEngine downgraded shares of Corium International from a hold rating to a sell rating in a research report on Thursday, August 24th. WBB Securities upgraded shares of Corium International to a buy rating and set a $13.00 price target on the stock in a research report on Friday, July 7th. Finally, Cantor Fitzgerald reiterated an overweight rating and set a $12.00 price target (up previously from $10.00) on shares of Corium International in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $11.79.
Corium International (NASDAQ:CORI) opened at 8.36 on Friday. The firm’s market capitalization is $298.80 million. The stock’s 50 day moving average is $8.28 and its 200-day moving average is $5.96. Corium International has a 52 week low of $2.67 and a 52 week high of $9.57.
Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.13. Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. The firm had revenue of $8.11 million during the quarter, compared to analyst estimates of $8.71 million. On average, equities research analysts expect that Corium International will post ($1.69) EPS for the current year.
In other Corium International news, major shareholder Life Sciences Maste Perceptive bought 301,004 shares of the business’s stock in a transaction on Friday, June 30th. The shares were bought at an average cost of $7.71 per share, for a total transaction of $2,320,740.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Timothy D. Sweemer sold 15,488 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $7.82, for a total transaction of $121,116.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,953 shares of company stock worth $705,258. 45.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORI. Bank of New York Mellon Corp increased its position in Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 13,683 shares during the last quarter. Royce & Associates LP increased its position in Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock worth $2,293,000 after buying an additional 370,600 shares during the last quarter. AWM Investment Company Inc. increased its position in Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock worth $10,248,000 after buying an additional 2,251,700 shares during the last quarter. Broadfin Capital LLC increased its position in Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock worth $11,650,000 after buying an additional 867,400 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Corium International during the first quarter worth about $11,096,000. Institutional investors own 90.14% of the company’s stock.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.